Literature DB >> 24786122

Detection of malignancy in body fluids: a comparison of the hematology and cytology laboratories.

Jaclyn L Jerz1, Rachel E Donohue, Rayomond R Mody, Mary R Schwartz, Dina R Mody, Arthur W Zieske.   

Abstract

CONTEXT: Body fluids submitted to the hematology laboratory for cell counts may also be examined for the presence of malignancy. Previous studies evaluating the hematology laboratory's performance at detecting malignancy in body fluids have reached conflicting conclusions.
OBJECTIVE: To investigate the hematology laboratory's ability to detect malignancy in body fluids by comparison with cytology.
DESIGN: Retrospective analysis of 414 body fluid samples during an 18-month period, with introduction of new quality assurance measures after the first 210 cases. If no concurrent cytology was ordered, results were compared with recent previous and/or subsequent cytologic, histologic, or flow cytometric diagnoses.
RESULTS: Of the initial 210 cases, the hematology laboratory detected 3 of 13 malignancies diagnosed by concurrent cytology (23% sensitivity), with no false-positives (100% specificity). Malignancy was not identified on retrospective review of the hematology slides in the 10 discrepant cases. After the initial study, educational sessions on morphology for the medical technologists and a more thorough hematology-cytology correlation policy were implemented. The subsequent 204 hematology laboratory cases had increased sensitivity for the detection of malignancy (60%; 6 of 10). Definitive features of malignancy were seen in only one discrepant hematology laboratory slide on retrospective review. This case had not been flagged for hematopathologist review. None of the discrepancies before or after implementation of the additional quality assurance measures impacted patient care.
CONCLUSIONS: Body fluid processing by the hematology laboratory is not optimized for the detection of malignancy. Concurrent cytologic examination is critical for the detection of malignancy, and needs to be considered as cost-saving measures are increasingly implemented.

Entities:  

Mesh:

Year:  2014        PMID: 24786122     DOI: 10.5858/arpa.2013-0295-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  1 in total

1.  Novel flowcytometry-based approach of malignant cell detection in body fluids using an automated hematology analyzer.

Authors:  Tomohiko Ai; Yoko Tabe; Hiroyuki Takemura; Konobu Kimura; Toshihiro Takahashi; Haeun Yang; Koji Tsuchiya; Aya Konishi; Kinya Uchihashi; Takashi Horii; Akimichi Ohsaka
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.